RetinalGenix Technologies (RTGN) Gains from Sales and Divestitures (2025)
RetinalGenix Technologies recorded quarterly Gains from Sales and Divestitures of $50000.0 in Q4 2025, little changed quarter-over-quarter from $50000.0 in Q3 2025.
RetinalGenix Technologies' Gains from Sales and Divestitures history runs 1 years deep, the most recent figure standing at $50000.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $50000.0; the TTM figure through Dec 2025 stood at $50000.0 (changed N/A YoY), while the FY2025 annual figure was $50000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $50000.0 for Q4 2025 at RetinalGenix Technologies, roughly flat from $50000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $50000.0 in Q3 2025 to a low of $50000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | RetinalGenix Technologies | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 50,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |